Podcasts

FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 6th 2020

Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon

July 2nd 2020

In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.

Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC

June 29th 2020

Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.

FDA Approval Insights: Olaparib in HRR-Mutant mCRPC

June 25th 2020

In our exclusive interview, Neeraj Agarwal, MD, discusses the recent FDA approval of olaparib in homologous recombination repair–mutant metastatic castration-resistant prostate cancer.

Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer

June 22nd 2020

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Integrating Nutrition Into the Continuum of Cancer Care

June 18th 2020

In our exclusive interview, Dr. Hegazi, shed light on nutrition-related issues among patients with cancer, early intervention strategies for patients who experience loss of muscle mass and function, and the use of specialized nutrients to prevent muscle degradation.

FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC

June 15th 2020

In our exclusive interview, Suresh S. Ramalingam, MD, discusses the FDA approval of nivolumab plus ipilimumab for the first-line treatment of patients with metastatic non–small cell lung cancer.

Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer

June 11th 2020

In our exclusive interview, Dr. Gradishar shares the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.

Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma

June 9th 2020

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma

June 8th 2020

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma

June 4th 2020

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.

Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era

June 2nd 2020

Mudit Chowdhary, MD, shares advice for family members living with patients with cancer, projects the long-term implications of the COVID-19 pandemic on clinical practice, provides insight on the effects of investigational treatments for patients with COVID-19, and details the protocols Rush University Medical Center has put into place to limit the spread of the virus.

Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology

May 28th 2020

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives

May 25th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.

FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma

May 21st 2020

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma

May 21st 2020

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

McGregor Details GU Treatment Guidelines During COVID-19 Pandemic

May 18th 2020

Bradley McGregor, MD, discusses the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.

FDA Approval Insights: Olaparib/Bevacizumab in HRD+ Advanced Ovarian Cancer

May 14th 2020

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer.

FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer

May 14th 2020

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in advanced ovarian cancer. 

Talking Tumors: Exploring Management Strategies in Multiple Myeloma

May 11th 2020

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.